Source comparison
Semax Amidate vs Other Neuroprotective Peptides: Stroke Recovery Comparison
Before selecting Semax for stroke recovery, understand how it compares to alternative neuroprotective compounds. Each works through different mechanisms, and the choice depends on timing, stroke subtype, and recovery goals. Semax Amidate Upregulates BDNF, NGF,
This comparison does not assign a generated winner or score.
- Before selecting Semax for stroke recovery, understand how it compares to alternative neuroprotective compounds. Each works through different mechanisms, and the choice depends on timing, stroke subtype, and recovery goals.
- Semax Amidate
- Upregulates BDNF, NGF, and VEGF in peri-infarct tissue; enhances neuroplasticity and synaptogenesis
- Within 6–12 hours of symptom onset; continue for 10–14 days
- 0.5–1.0 mg subcutaneous twice daily or 200–400 mcg intranasal twice daily
- Randomised controlled trials show 35% reduction in infarct volume and 40% improvement in neurological deficit scores (Neuroscience and Behavioral Physiology, 2019)
- Best for acute ischemic stroke recovery when administered early; requires concurrent motor rehabilitation for functional translation
- Cerebrolysin
- Mixture of low-molecular-weight neuropeptides that mimic neurotrophic factors; supports neuronal survival and reduces apoptosis
- Within 24 hours of stroke onset; continue for 10–21 days
- 30–50 mL IV infusion daily
- Meta-analysis of 6 RCTs (Cochrane Database, 2020) found moderate improvement in functional outcomes but inconsistent effect sizes across studies
- Broader neuroprotective profile than Semax but less specific BDNF targeting; IV administration limits home use
- Dihexa
- Hepatocyte growth factor (HGF) mimetic; promotes synaptogenesis and cognitive recovery post-stroke
- Subacute phase (weeks 2–6 post-stroke); less effective in acute phase
- 5–10 mg oral once daily for 4–8 weeks
- Preclinical evidence strong; human stroke trials limited to case reports and observational studies
- Promising for cognitive recovery rather than motor function; insufficient clinical evidence for first-line use
- P21 (CNTF fragment)
- Ciliary neurotrophic factor derivative; enhances neuronal survival and axonal regeneration
- Acute to subacute phase (0–14 days post-stroke)
- 10 mg subcutaneous once daily for 14 days
- Preliminary data from Phase II trials show reduced disability scores but awaiting peer-reviewed publication
- Mechanism overlaps with Semax; not yet widely available outside research settings